

E-mail Message

From: Anthony Gill [SMTP:Anthony.Gill@tga.gov.au]
To:
Cc: Lisa Studdert [NOTES:CN=Lisa Studdert/OU=TGA/O=Health@TTRA],
 Philippa Horner [SMTP:Philippa.Horner@tga.gov.au], Matthew Swainson
 [SMTP:Matthew.Swainson@tga.gov.au], Bill Turner
 [SMTP:Bill.Turner@tga.gov.au]
Sent: 18/9/2013 at 11:45 AM
Received: 18/9/2013 at 11:45 AM
Subject: Fw: TGA response re fluoridation 23 Aug 13 [SEC=UNCLASSIFIED]

Dear all

My proposed response to states and territories is:

At the current time the TGA does not have an update on this issue. The TGA will inform you all if there are any further developments.
 TGA's long term view that reticulated fluoridated water is not a therapeutic good remains extant.

Tony

Dr Tony Gill | MBBS MPH FAFPHM AFACHSM | Senior Medical Adviser | Office of
 Scientific Evaluation | Therapeutic Goods Administration | PO Box 100, WODEN
 ACT 2606 | Ph: 02 6232 8395 | Fax: 02 6232 8239 | Mob: 0432 758 162 | Email:
 anthony.gill@tga.gov.au

----- Forwarded by Anthony Gill/TGA/Health on 18/09/2013 12:04 PM -----

From: [REDACTED]
 To: [REDACTED] "Anthony.Gill@tga.gov.au"
 Cc: [REDACTED]

Date: 18/09/2013 10:46 AM
 Subject: RE: TGA response re fluoridation 23 Aug 13
 [SEC=UNCLASSIFIED]

Hi Tony

[REDACTED]

I don't think I've received an update from the TGA since your last email.

[REDACTED]

Have there been any developments?

[REDACTED]

Thanks,

[REDACTED]

Population Health | Department of Health and Human Services
 3/25 Argyle St Hobart [REDACTED] GPO Box 125 Hobart Tas 7001

A fair and healthy Tasmania

Ã,Ã

From: Anthony.Gill@tga.gov.au [mailto:Anthony.Gill@tga.gov.au]

Sent: Friday, 23 August 2013 2:23 PM

To: [REDACTED]

Subject: TGA response re fluoridation 23 Aug 13 [SEC=UNCLASSIFIED]

Ã,Ã

Dear all

In response to your emails relating to correspondence from [REDACTED]

The Therapeutic Goods Administration (TGA) is aware of the issues raised with state and territory health authorities about potential issues with the fluoridation of water with respect to the Therapeutic Goods Act 1989 and the Therapeutic Goods Advertising Code. Due to the complexity of the issues the TGA is further investigating the issues raised. The TGA is meeting early next week on these issues and will update the states and territories when further information is available.

Regards

Tony

Dr Tony Gill | MBBS MPH FAFPHM AFACHSM | Senior Medical Adviser | Office of Scientific Evaluation | Therapeutic Goods Administration | PO Box 100, WODEN ACT 2606 | Ph: 02 6232 8395 | Fax: 02 6232 8239 | Mob: 0432 758 162 | Email: anthony.gill@tga.gov.au

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information and has been sent in accordance with the TGA security policy.

If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author Immediately and delete all copies of this transmission."

Ã,Ã

CONFIDENTIALITY NOTICE AND DISCLAIMER

The information in this transmission may be confidential and/or protected by legal professional privilege, and is intended only for the person or persons to whom it is addressed. If you are not such a person, you are warned that any disclosure, copying or dissemination of the information is unauthorised. If you have received the transmission in error, please immediately contact this office by telephone, fax or email, to inform us of the error and to enable arrangements to be made for the destruction of the transmission, or its return at our cost. No liability is accepted for any unauthorised use of the information contained in this transmission.